SEC Form 4 · accession 0001209191-19-005805
UroGen Pharma Ltd. · URGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen Mullennix
Officer — Chief Operating Officer
Period of report
Jan 26, 2019
Accepted (ET)
Jan 29, 2019 · 5:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001668243
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $42.50 | Jan 26, 2019 | A | 15,000 | A | — | Jan 26, 2029 | Ordinary Shares | 15,000 | 15,000 | D |
| Restricted Stock UnitF2,F3 | — | Jan 26, 2019 | A | 5,000 | A | — | — | Ordinary Shares | 5,000 | 5,000 | D |
Explanation of responses
- F133.33% of the shares underlying the stock option will vest on January 26, 2020 and 12.5% of the remaining shares will vest in eight equal quarterly installments thereafter.
- F2Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- F333.33% of the RSUs will vest on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter.